A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa


ID# NCT04242446

Recruitment Status: recruiting as of August 2020.


Estimated Completion Date: May 2023

Sponsors and Collaborators: UCB Biopharma SRL

Brief Summary: The purpose of the study is to evaluate the efficacy and safety of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)

Locations: multiple locations please refer to link above for further information.

Please see link for complete trial details:



Contact: UCB Cares 1844599 ext 2273 


Get Updates

Affiliated With

© 2020 by HS Connect   |  HSConnect.org@gmail.com  |  PO Box 73244 Puyallup, WA 98373  |  253.256.1579